Latigo Biotherapeutics filed for an IPO intended to fund a clinical-stage pipeline of non-opioid pain management drugs, with its oral Nav1.8 inhibitor LTG-001 as the lead spending priority. The company plans to take LTG-001 into Phase 3 studies, including a bunion-surgery population, and a broader post-surgical and non-surgical setting trial. Topline readouts are targeted for the second half of 2027, and Latigo also plans to develop an intravenous formulation for hospital use and a potential bridge from inpatient postoperative care to outpatient pain management. The company is effectively positioning LTG-001 to compete in the Nav1.8-inhibitor space after Vertex’s Journax (suzetrigine) secured FDA approval. Latigo previously raised a $135 million Series A in 2024 and a $150 million Series B in 2025, signaling sustained investor backing. The filing also highlights other Nav1.8 assets, including LTG-321 in Phase 2 for osteoarthritis and preclinical LTG-418 for broader formulation possibilities.